Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Other Non-Current Liabilities (2012 - 2026)

Kamada's (KMDA) quarterly Other Non-Current Liabilities came in at $29.0 million in Q2 2026, down 11.65% on a YoY basis from $32.8 million in Q2 2025, and down 3.22% quarter-over-quarter from $29.9 million in Q1 2026.

Analysis

Kamada (KMDA) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Other Non-Current Liabilities for 9 consecutive years, with $29.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Liabilities fell 11.65% year-over-year to $29.0 million; the trailing twelve-month figure through Jun 2026 stood at $29.0 million (down 11.65% YoY), and the FY2025 full-year result was $30.1 million, down 8.24% from the prior year.
  • Other Non-Current Liabilities eased to $29.0 million in Q2 2026 per KMDA's latest filing, from $29.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $42.5 million in Q1 2022 and bottomed at $29.0 million in Q2 2026.
  • Historically, Other Non-Current Liabilities has averaged $34.9 million across 5 years, with a median of $34.3 million in 2023.
  • The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities decreased 15.07% in 2022, then retreated 4.25% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $37.3 million in 2022, then retreated by 7.85% to $34.4 million in 2023, then decreased by 4.55% to $32.8 million in 2024, then retreated by 8.24% to $30.1 million in 2025, then decreased by 3.82% to $29.0 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $29.0 million, $29.9 million, and $30.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 28.96 Mn
Mar 31, 2026 29.93 Mn
Dec 31, 2025 30.11 Mn
Sep 30, 2025 32.54 Mn
Jun 30, 2025 32.78 Mn
Mar 31, 2025 32.99 Mn
Dec 31, 2024 32.82 Mn
Sep 30, 2024 34.12 Mn
Jun 30, 2024 34.24 Mn
Mar 31, 2024 34.84 Mn
Dec 31, 2023 34.38 Mn
Sep 30, 2023 36.48 Mn
Jun 30, 2023 36.51 Mn
Mar 31, 2023 37.28 Mn
Dec 31, 2022 37.31 Mn
Sep 30, 2022 39.92 Mn
Jun 30, 2022 41.30 Mn
Mar 31, 2022 42.53 Mn
Dec 31, 2021 43.93 Mn
Dec 31, 2020 4.94 Mn